MS patients on anti-CD20 therapies are significantly less likely to discontinue treatment than those given other DMTs, a ...

In blood cancers such as chronic lymphocytic leukemia, B cells of the immune system multiply uncontrollably. One form of therapy involves labeling the CD20 protein on the surface of the B cells ...

Matthew Matasar, MD, discusses odronextamab and the ongoing phase 1 ELM-1 trial in patients with CD20-positive B-cell ...

ADI-001 is an allogeneic gamma delta CAR T-cell therapy that targets the B-cell antigen CD20. The Food and Drug Administration (FDA) has granted Fast Track designation to ADI-001 for the treatment ...